The Newsroom
Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the issuance of a new patent for the company’s SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. In addition, the company also provided an update on the timing of its anticipated clinical milestones.

Press Release
event
NeuroNova
Supernova
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
November 20, 2023
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result
November 14, 2023
Discover More
Discover More
Discover More
Publication
event
NeuroNova
Supernova
Annual Meeting – SITC 2023 – Nov 1st to 5th 2023 in San Diego, CA, USA.
November 3, 2023
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
November 3, 2023
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
November 1, 2023
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer
October 30, 2023
Discover More
Discover More
Discover More
Press Release
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
November 20, 2023
Discover More
Press Release
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result
November 14, 2023
Discover More
Press Release
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
November 3, 2023
Discover More
Press Release
Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
November 1, 2023
Discover More
Press Release
Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer
October 30, 2023
Discover More
Press Release
Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023
October 10, 2023
Discover More
Publication
event
NeuroNova
Supernova
Annual Meeting – SITC 2023 – Nov 1st to 5th 2023 in San Diego, CA, USA.
November 3, 2023
Discover More
Discover More
Publication
event
NeuroNova
Supernova
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial
August 22, 2021
Discover More
Discover More
Publication
event
NeuroNova
Supernova
Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies
August 15, 2020
Discover More
Discover More
Publication
event
NeuroNova
Supernova
Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects
August 15, 2020
Discover More
Discover More
Publication
event
NeuroNova
Supernova
Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.
May 25, 2020
Discover More
Discover More
Publication
event
NeuroNova
Supernova
Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
May 18, 2020
Discover More
Discover More
Media
Good Morning San Diego, Calidi Bio Treatments Discussed
April 13, 2019
Discover More
Media
KUSI San Diego News - Calidi Bio CEO, Allan Camaisa Interviewed
April 12, 2019
Discover More
In The News
Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market
October 9, 2023
Discover More
Discover More
In The News
Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player
October 9, 2023
Discover More
Discover More